Cellarity signs up with Excelra for GOSTAR database to enrich its drug discovery platform
PR86418
HYDERABAD, India and CAMBRIDGE, Mass., Nov. 5, 2020 /PRNewswire=KYODO JBN/ --
Excelra [https://www.excelra.com/], a leading global data science & data
analytics company, and Cellarity, a flagship pioneering company working on the
development of a new generation of medicines to treat diseases at the level of
cell behaviours, have today announced an agreement whereby Excelra will provide
Cellarity access to its Global Online Structure Activity Relationship database
(GOSTAR).
GOSTAR [https://www.excelra.com/discovery/#gostar] is the world's largest
small molecule medicinal chemistry intelligence platform that encompasses over
8 million compounds, linking chemical structure to biological, pharmacological
and therapeutic activities. With a vast knowledge base of 28 million SAR data
points, GOSTAR equips researchers in the early as well as optimization stages
of drug discovery.
Cellarity's drug discovery platform uses high-resolution biological data
and unique machine learning capabilities to pioneer an entirely new approach to
drug discovery. Cellarity is designing medicines that target and change cell
behaviors to unlock treatments in a large number of disease areas. "We are
looking forward to using high quality annotated GOSTAR data on millions of
small molecules, while leveraging Cellarity's proprietary AI/ML modules to
generate predictable drug-like molecules that ultimately guide the design of
novel Cell Behavior-Targeted therapies. Our preliminary assessment gives us the
confidence in the utility of GOSTAR database," said Ramakanth Sarabu, Head of
Chemistry, Cellarity.
"GOSTAR is a widely used structure activity relationship database in AI/ML
driven drug discovery programs. We strongly believe that this collaboration
equips AI/ML and medicinal chemistry researchers at Cellarity to utilize
curated interactions of millions of small molecules with potential drug targets
to generate novel compounds with desired pharmacological profiles," said
Raveendra Dayam, Director, Chemistry Services, Excelra.
About Cellarity:
Cellarity is a first-of-its-kind therapeutics company that is discovering
and developing medicines by studying and altering cell behaviors. Cellarity has
developed a powerful, generalizable platform harnessing single-cell
technologies, machine learning and proprietary data models of disease to unveil
the network state of a given cell. The platform digitizes and quantifies
cellular behaviors, unravels the network dynamics that govern those behaviors,
and generates medicines that can direct them. https://cellarity.com/
About Excelra:
Excelra's data science and data analytics solutions empower innovation in
life sciences. The Excelra Edge comes from a seamless amalgamation of
proprietary data assets, domain expertise and data science to accelerate drug
discovery & development. Visit www.excelra.com
Contact:
Dorothy Paul- Director Marketing
dorothy.paul@excelra.com
Logo: https://mma.prnewswire.com/media/692189/Excelra_Logo.jpg
Source: Excelra Knowledge Solutions Pvt Ltd
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。